BeiGene Ltd is a clinical-stage biopharmaceutical company engaged in the discovery & development of molecularly targeted & immuno-oncology drugs for the treatment of cancer. Its product includes BGB-3111, BGB-283 and BGB-290 and one immuno-oncology agent. This is an ADR of a company whose stock trades outside of the U.S. as the symbol HK:6160.

$256.81  +1.76 (0.69%)
As of 02/03/2023 15:59:55 EST     IEX book   CBOE book

Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Large cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  China
Country of incorporation:  
IPO date:  02/03/2016
Outstanding shares:  103,956,183
Average volume:  259,930
Market cap:   $26,433,978,213
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYYWPW6
Valuation   (See tab for details)
PE ratio:   -13.85
PB ratio:   4.45
PS ratio:   30.14
Return on equity:   -32.52%
Net income %:   -218.25%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy